Business Context and Reporting Period
Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: Eli Lilly operates primarily in the pharmaceutical products segment, with a smaller animal health segment. The company reported strong financial performance in the first half of 2008, driven by sales growth in key products like Cymbalta, Cialis, Humalog, Alimta, and Gemzar, as well as favorable foreign exchange rates.
Key Financial Metrics
| Metric (in millions) | Q2 2008 | Q2 2007 | 6 Months 2008 | 6 Months 2007 |
|---|---|---|---|---|
| Net Sales | $5,150.4 | $4,631.0 | $9,958.0 | $8,857.1 |
| Net Income | $958.8 | $663.6 | $2,023.1 | $1,172.3 |
| Earnings Per Share (Diluted) | $0.88 | $0.61 | $1.85 | $1.08 |
| Operating Cash Flow (6 Months) | $2,783.5 (2008) vs $1,480.3 (2007) | |||
| Cash & Equivalents (End of Period) | $2,868.3 (June 30, 2008) | |||
| Total Debt | $4,613.8 (June 30, 2008) | |||
| Gross Margin % | 76.7% | 78.4% | 76.8% | 78.3% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% in Q2 and 12% for the first six months of 2008 compared to the same periods in 2007. Growth was driven by volume increases and favorable foreign exchange rates.
- Profitability: Net income surged 44% in Q2 and 73% for the first half of 2008. This was significantly aided by a $210.3 million discrete income tax benefit in Q1 2008 resulting from the resolution of an IRS audit (2001-2004).
- Special Charges:
- Q2 2008: Incurred $88.9 million in restructuring/special charges and $57.1 million in asset impairments (manufacturing). Also recorded $35.0 million for acquired in-process R&D (TransPharma).
- Q1 2008: Incurred $145.7 million in charges primarily related to the termination of the AIR Insulin program and $87.0 million for acquired in-process R&D (BioMS).
- Comparison: 2007 special charges were significantly higher due to large in-process R&D write-offs from the acquisitions of ICOS ($303.5M) and Hypnion ($291.1M).
- Restatement: The company restated prior period balance sheets (2005-2007) to correct an understatement of the return reserve for future product returns by $247.5 million. This adjustment did not materially impact prior income statements.
Guidance, Outlook, and Risks
Financial Expectations for 2008
- Earnings Guidance: Revised full-year 2008 GAAP earnings guidance to $3.79 to $3.94 per share (down from previous $3.90 to $4.05) due to Q2 special charges.
- Sales Growth: Expected to grow in the high-single to low-double digits, revised upward from mid- to high-single digits due to strong foreign currencies.
- Expenses: Marketing, selling, and administrative (MSA) expenses and R&D expenses are expected to grow in the high-single digits, driven by foreign exchange, litigation costs, and prelaunch investments (e.g., prasugrel).
- Tax Rate: Excluding the Q1 IRS audit benefit, the effective tax rate is expected to be approximately 22%.
Key Risks and Contingencies
- Zyprexa Litigation: Significant ongoing product liability and patent litigation. The company has settled approximately 31,300 claims but faces remaining lawsuits and government investigations regarding marketing practices. Aggregate net pretax charges since 2005 total $1.61 billion.
- Patent Challenges: Facing generic competition challenges for Zyprexa (outside U.S.), Evista, Gemzar, and Strattera. An unfavorable outcome could materially impact results.
- Regulatory: Ongoing FDA review of prasugrel (extended to Sept 2008) and previous rejection of Zyprexa long-acting injection.
- Subsequent Events: Agreements signed in August 2008 to sell the Greenfield, Indiana site to Covance and outsource clinical services, which may result in significant future impairment and severance charges.
Investor Verification Checklist
- Restatement Impact: Verify the specific impact of the $247.5 million return reserve correction on current liquidity and future revenue recognition.
- Zyprexa Exposure: Assess the remaining financial exposure from unresolved Zyprexa product liability claims and government investigations, noting the company is self-insured for future losses.
- Patent Expirations: Monitor trial dates for generic challenges to Zyprexa (Canada/Germany/UK), Evista, Gemzar, and Strattera, as these could erode future revenue.
- Subsequent Charges: Track the magnitude of asset impairment and severance charges related to the August 2008 Greenfield site sale and outsourcing agreements.
- IRS Audit Resolution: Confirm the sustainability of the effective tax rate, noting the $210.3 million one-time benefit in Q1 2008.